Loading clinical trials...
Loading clinical trials...
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Conditions
Interventions
MEDI6469
Locations
1
United States
Portland Providence Medical Center
Portland, Oregon, United States
Start Date
March 14, 2016
Primary Completion Date
October 1, 2018
Completion Date
October 1, 2018
Last Updated
February 14, 2022
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Providence Health & Services
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions